AstraZeneca Proposes $10 Billion Acquisition of Rhythm Pharmaceuticals
AstraZeneca has submitted a non-binding offer to acquire obesity drug developer Rhythm Pharmaceuticals for approximately $10 billion.
Stocks · News reference
Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial
Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —Application supported by SAFFRON,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HUTCHMED Receives FDA Orphan Drug Designation for Sovleplenib in AIHA
The US Food and Drug Administration has granted Orphan Drug Designation to HUTCHMED's sovleplenib for the treatment of autoimmune hemolytic anemia.
AstraZeneca Makes $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca has reportedly submitted a $10 billion takeover offer to acquire Rhythm Pharmaceuticals for $124 per share.
'AstraZeneca Made $10 Billion Offer For Rhythm Pharmaceuticals; Rhythm Specializes In Treatments For Metabolic Conditions And Severe Obesity' - WSJ Exclusive
Bernstein Upgrades AstraZeneca Price Target and Reaffirms Outperform Rating
Bernstein has increased its price target for AstraZeneca PLC while maintaining an 'Outperform' rating on the stock.
AstraZeneca Announces Admission of Further Securities to Trading
AstraZeneca PLC has confirmed the admission of new shares to the London Stock Exchange following employee share scheme activity.